Saxenda vs Wegovy: Weight Loss, Dosage & Cost

Saxenda vs Wegovy comes down to two GLP-1 medications from the same maker, Novo Nordisk, that work in similar ways but differ in strength and schedule. Wegovy (semaglutide) is a once-weekly injection linked to about 15% average total body-weight loss in trials, while Saxenda (liraglutide) is a once-daily injection linked to about 8%. Wegovy is more effective on average and easier to keep up with, but Saxenda remains a useful shorter-acting option.

Both drugs belong to the GLP-1 receptor agonist class, meaning they mimic a natural gut hormone that curbs appetite and slows how quickly the stomach empties. That is why both can reduce how much you eat and help with weight management. If you want the underlying biology first, see how semaglutide works for weight loss. This article is informational only and reflects FDA labeling; the right medication and dose are decisions for you and a clinician.

Saxenda vs Wegovy at a glance

Feature	Saxenda	Wegovy
Active ingredient	Liraglutide	Semaglutide
Dosing frequency	Once daily	Once weekly
Doses	0.6 mg up to 3.0 mg per day	0.25 mg up to 2.4 mg per week
FDA-approved use	Chronic weight management	Chronic weight management
Weight loss	About 8% over 56 weeks	About 15% over 68 weeks
List price per month	About $1,300 to $1,349	About $1,300 to $1,349

How the two medications work

The core difference between the two is how long each molecule stays active in the body. Semaglutide, the drug in Wegovy, stays active roughly a week, so a single weekly injection maintains steady levels. Liraglutide, the drug in Saxenda, stays active only about a day, which is why it has to be injected every day to keep working. Both are given as subcutaneous injections using a prefilled pen.

Because they act on the same GLP-1 receptor, the felt effects are similar: less hunger, earlier fullness, and often smaller portions without the constant sense of deprivation. The difference in weight-loss results is largely one of degree. Semaglutide produces a stronger and more durable appetite effect at its target dose, which shows up in the trial numbers below.

Weight loss: what the trials show

The clearest way to compare effectiveness is to look at the main clinical trials for each drug. In the STEP-1 trial, adults taking Wegovy (semaglutide) lost about 15% of their total body weight on average over 68 weeks. In the SCALE trial, adults taking Saxenda (liraglutide) lost about 8% of their total body weight on average over 56 weeks. On average, Wegovy delivers close to twice the weight loss of Saxenda.

These are averages, and individual results vary widely around them. Some people on either drug lose much more, and some lose less. Response depends on dose tolerated, consistency, diet, activity, sleep, and other factors. The two trials also ran for slightly different lengths, 68 weeks for STEP-1 and 56 weeks for SCALE, so the numbers are best read as general benchmarks rather than a precise head-to-head. Even so, the gap between roughly 15% and roughly 8% is large enough that Wegovy stands out as the stronger option for most people. For a side-by-side view across the class, see GLP-1 weight loss results by drug, and for setting expectations before you start, read realistic weight loss goals on GLP-1. Averages describe groups, not any single person.

Dosing and titration

Both medications start low and step up slowly. This gradual titration gives the digestive system time to adjust and helps limit nausea and other early side effects.

Saxenda dosing

Saxenda is a daily injection. It typically begins at 0.6 mg per day and is increased weekly in steps until it reaches a maintenance dose of 3.0 mg per day, as tolerated. Because it is taken every day, that adds up to seven injections a week.

Wegovy dosing

Wegovy is a weekly injection. It usually begins at 0.25 mg per week and is stepped up over roughly 16 to 20 weeks to a maintenance dose of 2.4 mg per week, which is the maximum. That is one injection a week rather than seven. None of these figures are a prescription; a clinician sets your starting dose, your titration pace, and any adjustments. Do not change your dose on your own.

Convenience and adherence

Schedule is one of the most practical differences in the Saxenda vs Wegovy decision. Wegovy is once weekly, while Saxenda is once daily, which is seven injections a week versus one. For many people a weekly routine is simply easier to remember and stick with, and adherence tends to be better with Wegovy as a result. Missing an occasional daily dose has less impact than missing weekly ones, but the daily habit is harder to sustain over months and years.

Side effects for both drugs

Because Saxenda and Wegovy are in the same GLP-1 class, their side-effect profiles are broadly similar. The most common effects are gastrointestinal: nausea, diarrhea, vomiting, and constipation. These tend to be concentrated early on and during titration, when the dose is climbing, and often ease as the body adjusts. Both carry a boxed warning about thyroid C-cell tumors based on rodent studies, and both list other precautions in their labeling.

For a fuller breakdown, see Wegovy side effects and the class-wide GLP-1 side effects timeline, which shows when symptoms typically appear and fade. Slower titration and eating smaller, lower-fat meals are common ways clinicians help patients manage the early nausea. Staying hydrated and avoiding very large or greasy meals can also help. Report anything severe or persistent to your prescriber, and do not simply push through symptoms that are not improving.

Cost and coverage

Both drugs are branded and expensive. At list price, each runs roughly $1,300 to $1,349 a month before insurance or discounts. Insurance coverage for weight-management drugs varies a lot by plan, so out-of-pocket cost can differ widely. Wegovy also has a manufacturer cash-pay option through NovoCare, priced around $499 a month for eligible self-pay patients, which can lower the barrier for people paying out of pocket.

Price and coverage often end up driving the real-world choice as much as efficacy does. For details on paying without insurance, see Wegovy cost without insurance. Prices and program terms change, so confirm current figures with the pharmacy and manufacturer.

Which might fit better

On average, Wegovy is the more effective and more convenient option, and it is often the first choice when the goal is maximum weight loss with the simplest schedule. Saxenda is sometimes chosen when a shorter-acting medication is preferred, or when semaglutide is not tolerated or is unavailable due to supply. A daily drug clears the body faster, which some clinicians and patients see as an advantage in specific situations.

Both are FDA-approved for chronic weight management, so both are legitimate tools. If you are also weighing semaglutide against tirzepatide, the comparison in Wegovy vs Zepbound is a useful next read, and you can confirm approval status in FDA-approved GLP-1 medications. The best fit depends on your health history, insurance, tolerance, and preferences, which is a conversation to have with a clinician.